Kenvue Inc. (KVUE) to Issue Quarterly Dividend of $0.21 on February 26th

Kenvue Inc. (NYSE:KVUE) declared a quarterly dividend on Thursday, January 16th,Wall Street Journal reports. Shareholders of record on Wednesday, February 12th will be paid a dividend of 0.205 per share on Wednesday, February 26th. This represents a $0.82 annualized dividend and a yield of 4.05%. The ex-dividend date of this dividend is Wednesday, February 12th.

Kenvue has a dividend payout ratio of 64.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Kenvue to earn $1.30 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 63.1%.

Kenvue Trading Up 2.2 %

Shares of KVUE stock opened at $20.23 on Monday. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $21.54 and its two-hundred day moving average is $21.97. The company has a market capitalization of $38.79 billion, a P/E ratio of 38.17, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts forecast that Kenvue will post 1.05 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Citigroup reduced their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.